<DOC>
	<DOCNO>NCT00871351</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety atorvastatin 10 mg ezetimibe 10 mg coadministration Japanese participant hypercholesterolemia whose low-density lipoprotein ( LDL ) -cholesterol level reach lipid management target value atorvastatin 10 mg alone , versus increase dose atorvastatin 20 mg change rosuvastatin 2.5 mg .</brief_summary>
	<brief_title>Evaluation Ezetimibe Atorvastatin Coadministration Versus Atorvastatin Rosuvastatin Monotherapy Japanese Patients With Hypercholesterolemia ( Study P06027 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>atorvastatin 10 mg monotherapy 4 week longer start 4week washout low density lipoproteincholesterol ( LDLC ) level reach follow lipid management target value treatment : Category I ( lowrisk group ) risk factor LDLC &lt; 160 mg/dL ; Category II ( midrisk group ) 12 risk factor LDLC level LDLC &lt; 140 mg/dL ; Category III ( highrisk group ) 3 risk factor LDLC &lt; 120 mg/dL ; participant history coronary artery disease LDLC &lt; 100 mg/dL . outpatient men woman , age 20 year older fast triglyceride level start washout treatment period exceed 400 mg/dL . homozygous familial hypercholesterolemia . creatine phosphokinase ( CPK ) &gt; 2 time upper limit normal ( X ULN ) start washout treatment period . glycosylated hemoglobin ( HbA1c ) &gt; =8ï¼… start washout treatment period . severe hepatic function disorder , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2X ULN start washout treatment period . hypersensitivity ezetimibe , atorvastatin , rosuvastatin tablet . pregnant lactate discontinue use atorvastatin 10 mg less 4 week start treatment period ( however , participant take atorvastatin 10 mg test conduct start observation period , period discontinuation 27 day allow . ) cyclosporine treatment hyperlipidemia associate hypothyroidism , obstructive gall bladder biliary disease , chronic renal failure , and/or pancreatitis . hyperlipidemia associate drug administration cause adverse serum lipid effect . participation clinical study within 4 week washout cancer cancer history within previous 5 year , except successfully treat basal cell carcinoma skin .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>